SCHEMBL977680

SCHEMBL977680

c1ccc(COc2ccc(C3(c4ccc(-c5ccncc5)cc4)CCCCC3)cc2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 1/20 0.47
▸ SMO Q99835 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ CYP3A4 P08684 2/20 0.43
▸ CYP2D6 P10635 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ PARP10 Q53GL7 1/20 0.43
▸ HPGD P15428 1/20 0.42
▸ SYK P43405 7/20 0.41
▸ AURKB Q96GD4 1/20 0.41
▸ INCENP Q9NQS7 1/20 0.41
▸ PSMB1 P20618 1/20 0.40
▸ PSMB5 P28074 1/20 0.40
▸ PSMB2 P49721 1/20 0.40
▸ ALOX5AP P20292 3/20 0.40
▸ PDE10A Q9Y233 1/20 0.39
▸ ADAMTS4 O75173 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL976155 0.96 MAPK14 (0.47) MAPK14SMOKDM4EALDH1A1SMN1; SMN2
SCHEMBL977196 0.89 CYP3A4 (0.44) MAPK14SMOKDM4EALDH1A1SMN1; SMN2
SCHEMBL975521 0.85 CYP3A4 (0.45) KDM4EALDH1A1SMN1; SMN2CYP3A4CYP2D6
SCHEMBL975773 0.84 CYP1A2 (0.47) MAPK14SMOKDM4EALDH1A1SMN1; SMN2
SCHEMBL975660 0.82 KDM4E (0.46) KDM4EALDH1A1SMN1; SMN2CYP3A4CYP2D6
SCHEMBL977752 0.82 PARP10 (0.50) KDM4EALDH1A1SMN1; SMN2CYP3A4CYP2D6
SCHEMBL977769 0.81 NPC1 (0.43) MAPK14SMOKDM4EALDH1A1SMN1; SMN2
SCHEMBL976551 0.81 PARP10 (0.56) MAPK14SMOKDM4EALDH1A1SMN1; SMN2
SCHEMBL3713837 0.80 HPGD (0.41) KDM4EALDH1A1SMN1; SMN2CYP3A4CYP2D6
SCHEMBL977374 0.80 MAPT (0.43) MAPK14SMOKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003815-A1 DIPHENYL SUBSTITUTED CYCLOALKANES MERCK & CO., INC. 2011-01-06 — — US disclosed
EP-2209761-A1 DIPHENYL SUBSTITUTED CYCLOALKANES Merck Sharp & Dohme Corp. (US) 2010-07-28 — — EP disclosed
WO-2009048547-A1 DIPHENYL SUBSTITUTED CYCLOALKANES MERCK & CO., INC. (US) 2009-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003815-A1 DIPHENYL SUBSTITUTED CYCLOALKANES PTGIS, PTGS1, LTC4S MAPK14 2934/4885SMO 2800/4885KDM4E 3639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback